Ocugen Execs Hit With Derivative Suit Over Shoddy Controls
By Sydney Price · July 18, 2024, 6:46 PM EDT
The top brass at biopharmaceutical company Ocugen Inc. were hit with a derivative suit alleging the company's lack of effective internal financial controls caused it to be misvalued and allowed shareholders...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login